JP2017528468A5 - - Google Patents

Download PDF

Info

Publication number
JP2017528468A5
JP2017528468A5 JP2017513506A JP2017513506A JP2017528468A5 JP 2017528468 A5 JP2017528468 A5 JP 2017528468A5 JP 2017513506 A JP2017513506 A JP 2017513506A JP 2017513506 A JP2017513506 A JP 2017513506A JP 2017528468 A5 JP2017528468 A5 JP 2017528468A5
Authority
JP
Japan
Prior art keywords
trastuzumab
population
antibody
relative frequency
galactose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017513506A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017528468A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/070285 external-priority patent/WO2016037947A1/en
Publication of JP2017528468A publication Critical patent/JP2017528468A/ja
Publication of JP2017528468A5 publication Critical patent/JP2017528468A5/ja
Withdrawn legal-status Critical Current

Links

JP2017513506A 2014-09-10 2015-09-04 ガラクトース操作型免疫グロブリン１抗体 Withdrawn JP2017528468A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14184201.3 2014-09-10
EP14184201 2014-09-10
US201462095912P 2014-12-23 2014-12-23
US62/095,912 2014-12-23
PCT/EP2015/070285 WO2016037947A1 (en) 2014-09-10 2015-09-04 Galactoengineered immunoglobulin 1 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020156251A Division JP2021006540A (ja) 2014-09-10 2020-09-17 ガラクトース操作型免疫グロブリン１抗体

Publications (2)

Publication Number Publication Date
JP2017528468A JP2017528468A (ja) 2017-09-28
JP2017528468A5 true JP2017528468A5 (enExample) 2018-09-27

Family

ID=51518624

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017513506A Withdrawn JP2017528468A (ja) 2014-09-10 2015-09-04 ガラクトース操作型免疫グロブリン１抗体

Country Status (5)

Country Link
US (2) US20170253661A1 (enExample)
EP (2) EP3567056A1 (enExample)
JP (1) JP2017528468A (enExample)
CN (2) CN114181312A (enExample)
WO (1) WO2016037947A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117887794A (zh) * 2016-12-21 2024-04-16 豪夫迈·罗氏有限公司 用于体外糖工程化抗体的方法
JP6931058B2 (ja) * 2016-12-21 2021-09-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗体のインビトロ糖鎖工学における酵素の再使用
KR102317884B1 (ko) * 2016-12-21 2021-10-26 에프. 호프만-라 로슈 아게 항체의 시험관 내 당조작
CA3110530A1 (en) * 2018-09-11 2020-03-19 Amgen Inc. Methods of modulating antibody-dependent cell-mediated cytotoxicity
WO2021072244A1 (en) * 2019-10-11 2021-04-15 Beth Israel Deaconess Medical Center, Inc. Anti-tn antibodies and uses thereof
EP4204005A1 (en) * 2020-08-31 2023-07-05 Sab, Llc Ungulate-derived polyclonal immunoglobulin specific for coronavirus protein and uses thereof
EP4119672A1 (en) * 2021-07-14 2023-01-18 Sartorius Stedim Cellca GmbH Method of modulating the extent of galactosylation of proteins in mammalian producer cells
CN114167060B (zh) * 2021-11-25 2022-08-05 辽宁师范大学 一种肝癌生物标志物及检测肝癌的试剂盒
WO2023102398A2 (en) * 2021-11-30 2023-06-08 Sab, Llc Ungulate-derived polyclonal immunoglobulin specific for influenza virus and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
ES2434840T3 (es) 1995-07-27 2013-12-17 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
GB9603256D0 (en) * 1996-02-16 1996-04-17 Wellcome Found Antibodies
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
NZ507557A (en) 1998-05-06 2003-10-31 Genentech Inc Protein purification by ion exchange chromatography
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
FR2861080B1 (fr) * 2003-10-20 2006-02-17 Lab Francais Du Fractionnement Anticorps presentant un taux de fucose et de galactose optimise
US9296820B2 (en) * 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
PT1896071E (pt) * 2005-06-30 2015-07-09 Janssen Biotech Inc Métodos e composições com melhorias na atividade terapêutica
MX2009007139A (es) * 2006-12-28 2009-10-08 Centocor Ortho Biotech Inc Metodos y vectores para generar inmunoglobulinas no sialiladas.
US10087236B2 (en) * 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
JP5956982B2 (ja) * 2010-05-27 2016-07-27 メルク・シャープ・エンド・ドーム・コーポレイション 改善された特性を有する抗体の製造方法
PT2603528T (pt) * 2010-08-10 2016-12-01 Glycotope Gmbh Anticorpos glicosilados em fab
CN104168913A (zh) * 2011-08-10 2014-11-26 法国化学与生物科技实验室 高半乳糖基化抗体
SG2014012470A (en) * 2011-10-05 2014-06-27 Hoffmann La Roche Process for antibody g1 glycoform production
WO2014125377A2 (en) * 2013-02-13 2014-08-21 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Highly galactosylated anti-her2 antibodies and uses thereof

Similar Documents

Publication Publication Date Title
JP2017528468A5 (enExample)
WO2013082519A3 (en) Nucleotide-specific recognition sequences for designer tal effectors
US9689016B2 (en) Method for in vivo production of deglycosylated recombinant proteins used as substrate for downstream protein glycoremodeling
CA2922888C (en) Cells producing fc containing molecules having altered glycosylation patterns and methods and use thereof
ZA201905673B (en) Alpha-amylase variants
JP2016508515A5 (enExample)
EP4640239A3 (en) Site-specific glycoengineering of targeting moieties
WO2014202616A3 (en) Rasamsonia gene and use thereof
WO2017011773A3 (en) Codon-optimized nucleic acids encoding antibodies
WO2010132659A3 (en) Anti-human cd52 immunoglobulins
JP2017510274A5 (enExample)
MX348071B (es) Variantes de fc.
WO2011123830A3 (en) Alpha 1-antitrypsin compositions and methods of making and using same
WO2004074497A3 (en) Endomannosidases in the modification of glycoproteins in eukaryotes
NZ598351A (en) Il-17 binding compounds and medical uses thereof
EA201071108A1 (ru) Способ и система обеспечения контроля за изготовлением изделий
WO2010139736A3 (de) Rekombinante herstellung von peptiden
WO2012142434A8 (en) Aav mediated ctla-4 gene transfer to treat sjogren's syndrome
WO2015199387A3 (ko) 가용성 단백질 발현량 및 활성이 증대된 헬리코박터 파일로리 유래 α-1,3 푸코실 전달효소의 유전자와 단백질 및 α-1,3 푸코실올리고당 생산에의 응용
WO2021123184A3 (en) Alpha-amylase variants
NZ742745A (en) Variants of chymosin with improved milk-clotting properties
JP2017505620A5 (enExample)
JP2020501577A5 (enExample)
PH12017502299A1 (en) Method for producing a demineralised milk protein composition, suitable in particular for the organic sector, and demineralised milk protein composition
ZA202205485B (en) L-methionine producing microorganism to which protein encoded by foreign metz gene is introduced and method for producing l-methionine using same